Elrashed B. Yasin

Methylation Profiling SOCS2 in Philadelphia-Negative Myeloproliferative Neoplasm

Elrashed B. Yasin · Journal of Pharmaceutical Research International · 2021

The Janus kinase signal transducer and activator of transcription (JAK / STAT) signalling, which is crucial in Philadelphia-negative myeloproliferative neoplasms’ (MPNs), is negatively regulated by molecules such as SOCS, CISH, and SHP1. SOCS2 methylation has been studied in MPN...

Open access Research Article 10.9734/jpri/2021/v33i47A33033

Calreticulin and JAK2 Exon 12 Mutation Screening in Patients with Myeloproliferative Neoplasms’ in Jeddah Region, Saudi Arabia

Heba Alkhatabi, Heyam Abdulqayoom, Raed Alserihi, Raed Felimban, Aisha Elaimi, Zinab Allala, Afaf Magboli, Salem Bahashwan, Hashem Alsalmi, Abdulelah Shihah, Adel Abuzenadah & Elrashed B. Yasin · Journal of Pharmaceutical Research International · 2021

Background: The JAK2 V617F mutation’s discovery has largely facilitated the comprehension of the myeloproliferative neoplasms’(MPNs) pathogenesis. In recent times, calreticulin (CALR) mutations have been detected in patients with JAK2V617F negative primary myelofibrosis (PMF), an...

Open access Research Article 10.9734/jpri/2021/v33i47A33029